Startups channel feed – Endpoints News

Startups channel feed

Sean Nolan gathers AveXis alumni to launch another biotech. Is it another race-to-IPO?

5 years ago

Flagship upstart Cellarity gathers $123M to finance its exploration of cell behavior, blazing a new path to building a broad pipeline

5 years ago

The mRNA era is here. MPM believes the future belongs to oRNA — and Big Pharma wants a seat at the table

5 years ago

Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot

5 years ago

Francesco De Rubertis makes his legacy play, recruiting star execs and rolling up 10 biotech startups into a $250M gamble on creating something new in pharma

5 years ago

George Church and an entrepreneurial postdoc join the hunt for AAV 2.0 with a new vector-cloaking technology

5 years ago

With a roster of gene therapy vets, Forbion makes a bet on 'relatively empty space' of vectorized antibodies

5 years ago

A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate's lab

5 years ago

The inside story behind the fall of Laurie Glimcher's big I/O startup and the often tense equation of science and money

5 years ago

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

5 years ago

As targeted therapies get ever more precise, Deerfield unveils $50M bet on a Harvard professor's chemistry insights

5 years ago

Buried in Immunocore's IPO filings? A kickback scheme from a now former employee

5 years ago

Neuvogen uncloaks with broad plan of attack for whole-cell cancer vaccines, clinical hopes within the year

5 years ago

An ambitious GV-backed gene editing upstart re-emerges as a one-drug kidney company

5 years ago

A longtime Pfizer chief's ultra-quiet biotech re-emerges with new cash and plans for the clinic

5 years ago

Flagship christens the latest startup to join the drug discovery fleet, this time focused on the lessons of cell death

5 years ago

Genentech and Biogen roll the dice on an upstart biotech with a new siRNA approach — going deep into the brain for targets in neurodegeneration

5 years ago

Michael Ehlers is betting $40M that an AI outfit has figured out how to beat the blockbuster IL-2 challenge

5 years ago

Rick Klausner fronts cash for his fungus outfit LifeMine and brings on Nobel laureate to further push cancer discovery

5 years ago

Dermira vets license back candidates from Eli Lilly to launch their own upstart

5 years ago

With decades in gene therapy under his belt, Ronald Crystal launches new venture with up to 18 candidates in the pipe

5 years ago

Gary Glick, Keith Flaherty now have $270M to realize their vision for Precision Oncology 2.0 — we'll just have to wait for the details

5 years ago

Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another

5 years ago

Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years

5 years ago

First page Previous page 47 48 495051 52 53 Next page Last page